Navigation Links
Battelle Collaborating With Korean Partners to Advance Energy Efficiency and Health and Life Sciences Initiatives in Korea
Date:5/6/2008

COLUMBUS, Ohio, May 6 /PRNewswire-USNewswire/ -- Developing a strong pharmaceutical industry is a key issue in Korea. So much so, that Battelle-Korea, Battelle, Chuncheon City, Gangwon Province and YuYu Inc., intend to collaborate and address the issue. A Korean corporation named International Scientific Standard (ISS), Inc., will be formed to develop a bioequivalency business in Chuncheon City, Gangwon Province, that will meet international Good Laboratory Practices (GLP) standards.

ISS will perform studies that enable Korean pharmaceutical products to be certified by the U.S. Food and Drug Administration (FDA) and regulatory bodies in many countries around the world. This capability of ISS will enable pharmaceutical products developed by the Korean domestic companies to be sold in overseas markets, such as the U.S. and Europe.

In addition, the collaborators will work on developing energy efficiency technologies and buildings. They will work together to develop a roadmap toward greater energy efficiency in Gangwon Province. This roadmap will identify manufacturing, service, and research and development (R&D) opportunities.

"This is a very promising collaboration," said Joan Adams, President and CEO of Battelle Korea. "The opportunities to develop a stronger pharmaceutical industry, advance biotechnology initiatives, and provide greater energy efficiency can only be achieved through working cooperatively."

In attendance at the May 5 signing ceremony at Battelle's headquarters in Columbus, Ohio were: Joan Adams, Battelle Korea; Barbara Kunz, Battelle President for Health and Life Sciences Global Business; Seungpil Yu, Chairman and CEO of YuYu Inc., a; Jin-sun Kim, Governor of Gangwon Province, and Kwang Jun Lee, Mayor of Chuncheon City.

YuYu Inc. is a pharmaceutical company listed in the Korea Stock Exchange.

Battelle is the world's largest non-profit independent research and development organization, providing innovative solutions to the world's most pressing needs through its four global businesses: Laboratory Management, National Security, Energy Technology, and Health and Life Sciences. It advances scientific discovery and application by conducting $4 billion in global R&D annually through contract research, laboratory management and technology commercialization. Headquartered in Columbus, Ohio, Battelle oversees 20,400 employees in more than 120 locations worldwide, including seven national laboratories which Battelle manages or co-manages for the U.S. Department of Energy and the U.S. Department of Homeland Security.

Battelle also is one of the nation's leading charitable trusts focusing on societal and economic impact and actively supporting and promoting science and math education. For more information visit http://www.battelle.org or contact Media Relations Manager Katy Delaney at (410) 306-8638 or at delaneyk@battelle.org.


'/>"/>
SOURCE Battelle
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle
2. MEDRAD, Battelle Win Medical Design Excellence Award for MEDRAD XDS(TM) Extravasation Detector
3. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
4. Korean Food and Drug Administration Approval for ActiPatch Achieved
5. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
8. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
9. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" or ... its major shareholders, Clean Technology Fund I, LP and ... based venture capital funds which together hold ... a fully diluted, as converted basis), that they have ... entire equity holdings in Biorem to TUS Holdings Co. ...
(Date:6/27/2016)... ... 2016 , ... Parallel 6 , the leading software as a service ... Virtual Patient Encounter CONSULT module which enables both audio and video telemedicine communication ... , Using the CONSULT module, patients and physicians can schedule a face to face ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):